ERBB2 and breast carcinoma: Taselisib is an indole-fused benzoxazepine that has been tested in combination with an estrogen receptor antagonist in phase III clinical trials for estrogen receptor (ER) positive and HER2 negative advanced breast cancer patients with mutated PIK3CA 14.